✦ LIBER ✦

A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study

✍ Scribed by William S. Dalton; John J. Crowley; Sydney S. Salmon; Thomas M. Grogan; Leslie Rodgers Laufman; Geoffrey R. Weiss; John D. Bonnet

Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 608 KB
Volume: 75
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19950201)75:3<815::aid-cncr2820750311>3.0.co;2-r

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase III study of PSC-833 (valspodar) i

Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95) : A trial of the Eastern Cooperative Oncology Group

✍ William R. Friedenberg; Montserrat Rue; Emily A. Blood; William S. Dalton; Chaim 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB 👁 1 views

Treatment of Bendamustine and Prednisone

Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)

✍ W. Pönisch; P. S. Mitrou; K. Merkle; M. Herold; M. Assmann; G. Wilhelm; K. Dachs 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 344 KB